Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 17/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955718 | 0.82 | PIK3C3 (0.66) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL15763770 | 0.76 | PIK3C3 (0.83) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9956079 | 0.76 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957844 | 0.76 | PIK3C3 (0.83) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL16390779 | 0.75 | PIK3C3 (0.94) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL16390656 | 0.75 | PIK3C3 (0.98) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL8229238 | 0.75 | MAPK8 (0.52) | PIK3C3MAPK8MAPK9MAPK10MKNK1 | |
| SCHEMBL16390818 | 0.75 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957746 | 0.74 | PIK3C3 (0.80) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9956410 | 0.74 | PIK3C3 (0.70) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | PIK3C3 210/4885PIK3CD 39/4885PIK3CA 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.